Evidence map›Paper›PMID 25627637›Full record

ArticleLeukemia2015

Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet.

E Lengfelder, F Lo-Coco, L Ades, P Montesinos, D Grimwade, B Kishore, S M Ramadan, M Pagoni, M Breccia, A J G Huerta and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 73 citations in OpenAlex.

  1. Trial
  2. Article
  3. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia.Clinical lymphoma, myeloma & leukemia · 2024
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. [Advances in autologous stem cell transplantation for acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 14 institutions in 8 countries.

E LengfelderDepartment of Hematology and Oncology, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany.
F Lo-CocoDepartment of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
L AdesHopital St Louis, Paris, France.
P MontesinosDepartment of Hematology, University Hospital La Fe and Department of Medicine, University of Valencia, Valencia, Spain.ORCID 0000000232755593
D GrimwadeDepartment of Medical and Molecular Genetics, King's College London London, UK.
B KishoreHeartofengland NHS Foundation Trust, Birmingham, UK.
S M RamadanDepartment of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
M PagoniEvangelismos Hospital, Athens, Greece.
M BrecciaDepartment of Cellular Biotechnology and Hematology, Sapienza University, Rome, Italy.
A J G HuertaHospital General de Alicante, Alicante, Spain.
A M NlogaHopital St Louis, Paris, France.
J D González-SanmiguelHospital Insular de Las Palmas, Las Palmas, Spain.
A SchmidtDepartment of Hematology and Oncology, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany.
J-F LambertService d'Hématologie du CHUV, Lausanne, Switzerland.
S LehmannDepartment of Hematology, Karolinska University Hospital, Stockholm, Sweden.
E Di BonaSan Bortolo Hospital, Vicenza, Italy.
B CassinatHopital St Louis, Paris, France.
W-K HofmannDepartment of Hematology and Oncology, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany.
D GörlichInstitute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany.
M-C SauerlandInstitute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany.
P FenauxHopital St Louis, Paris, France.
M SanzDepartment of Hematology, University Hospital La Fe and Department of Medicine, University of Valencia, Valencia, Spain.
European LeukemiaNet
Hôpital Saint-Louis · FRHeidelberg University · DEUniversitat de València · ESUniversity of Münster · DEUniversity of Rome Tor Vergata · ITEvangelismos Hospital · GRHeart of England NHS Foundation Trust · GBHospital General Universitario de Alicante Doctor Balmis · ESHospital Universitario Insular de Gran Canaria · ESKarolinska University Hospital · SEKing's College London · GBOspedale San Bortolo · ITSapienza University of Rome · ITUniversity Hospital of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2008, a European registry of relapsed acute promyelocytic leukemia was established by the European LeukemiaNet. Outcome data were available for 155 patients treated with arsenic trioxide in first relapse. In hematological relapse (n=104), 91% of the patients entered complete hematological remission (CR), 7% had induction death and 2% resistance, 27% developed differentiation syndrome and 39% leukocytosis, whereas no death or side effects occurred in patients treated in molecular relapse (n=40). The rate of molecular (m)CR was 74% in hematological and 62% in molecular relapse (P=0.3). All patients with extramedullary relapse (n=11) entered clinical and mCR. After 3.2 years median follow-up, the 3-year overall survival (OS) and cumulative incidence of second relapse were 68% and 41% in hematological relapse, 66% and 48% in molecular relapse and 90 and 11% in extramedullary relapse, respectively. After allogeneic or autologous transplantation in second CR (n=93), the 3-year OS was 80% compared with 59% without transplantation (n=55) (P=0.03). Multivariable analysis demonstrated the favorable prognostic impact of first remission duration ⩾1.5 years, achievement of mCR and allogeneic or autologous transplantation on OS of patients alive after induction (P=0.03, P=0.01, P=0.01) and on leukemia-free survival (P=0.006, P<0.0001, P=0.003), respectively.

Indexed as

AdolescentAdultAgedAged, 80 and overAntineoplastic AgentsArsenicalsArsenic TrioxideCell DifferentiationChildChild, PreschoolDisease-Free SurvivalEuropeFemaleHumansInternational CooperationLeukemia, Promyelocytic, AcuteAntineoplastic AgentsArsenicalsArsenic TrioxideOxides

Identifiers

PMID25627637
OpenAlexW2019187521

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.